Medicamen Biotech Limited — Others, 23-04-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Medicamen Biotech Limited has announced a board meeting to review the securities dematerialized and rematerialized during Q1 FY2025. The company confirmed that all securities involved have been duly listed on the relevant stock exchanges. Additionally, securities processed for dematerialization were verified and cancelled in accordance with the required timelines.

This transparency in securities management reflects the company's commitment to maintaining efficient operations, which may enhance shareholder trust. Given this proactive approach, investors may view this development favorably, signaling a stable corporate governance environment. However, ongoing monitoring of securities activity remains prudent.